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Abstract
Background: Urinary, sexual and anorectal sequelae are frequent after rectal cancer surgery and were found to be
related to intraoperative neurogenic impairment. Neuromonitoring methods have been developed to identify and
preserve the complex pelvic autonomic nervous system in order to maintain patients’ quality of life. So far no
randomized study has been published dealing with the role of neuromonitoring in rectal cancer surgery.
Methods/design: NEUROS is a prospective two-arm randomized controlled multicenter clinical trial comparing the
functional outcome in rectal cancer patients undergoing total mesorectal excision (TME) with and without pelvic
intraoperative neuromonitoring (pIONM). A total of 188 patients will be included. Primary endpoint is the urinary
function measured by the International Prostate Symptom Score. Secondary endpoints consist of sexual, anorectal
functional outcome and safety, especially oncologic safety and quality of TME. Sexual function is assessed in females
with the Female Sexual Function Index and in males with the International Index of Erectile Function. For evaluation of
anorectal function the Wexner-Vaizey score is used. Functional evaluation is scheduled before radiochemotherapy (if
applicable), preoperatively (baseline), before hospital discharge, 3 and 6 months after stoma closure and 12 months after
surgery. For assessment of safety adverse events, the rates of positive resection margins and quality of mesorectum are
documented.
Discussion: This study will provide high quality evidence on the efficacy of pIONM aiming for improvement of
functional outcome in rectal cancer patients undergoing TME.
Trial registration: Clinicaltrials.gov: NCT01585727. Registration date is 04/25/2012
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Background
Urinary, sexual and anorectal functional disturbances do
frequently occur after total mesorectal excision (TME) for
rectal cancer and may tremendously impair patients’ quality
of life. In order to reduce the dysfunction rates it is recom-
mended to identify and preserve the pelvic autonomic
nerves during the surgical procedure. However, visual nerve
identification especially of those located in the minor pelvis
(inferior hypogastric plexus, pelvic splanchnic nerves and
neurovascular bundles) is challenging due to the complexity
of neural distribution and further patient as well as surgery
related factors such as a narrow or deep pelvic cavity, the
appearance of a voluminous mesorectum, severe obesity,
previous pelvic surgery, neoadjuvant chemoradiotherapy,
locally advanced tumors with anterior quadrant involve-
ment, supra-anal or juxta-anal tumors, adherence or infil-
tration of adjacent organs, a bloody situs, use of additional
diathermy coagulation and the applied dissection tech-
niques [1–4]. Therefore, poor nerve visualization and lack
of neuroanatomical knowledge will consequently result in
inadvertent nerve damage.
Pelvic intraoperative neuromonitoring (pIONM) was
introduced to rectal cancer surgery to serve as a novel
method for improvement of nerve identification and fur-
ther verification of its functional integrity. In previous
investigations it could be already shown that the electro-
physiological nerve identification is superior to sole vis-
ual assessment [5]. A recently developed pIONM
method is based on electric stimulations of pelvic auto-
nomic nerves under simultaneous observation of proc-
essed electromyography (EMG) of the internal anal
sphincter (IAS) and manometry of the urinary bladder.
Its suitability for accurate assessment of nerve function
and its predictive potential of functional outcome has
been demonstrated by previous non-randomized single-
center studies [6, 7]. In a recent case-control study
pIONM controlled TME in rectal cancer patients was
found to offer better functional outcome compared to
patients undergoing surgery without the use of this
method [8]. An actual retrospective investigation sup-
ports these findings by demonstrating superior urogeni-
tal function in patients undergoing rectal cancer surgery
with electrophysiological control [9]. The results are en-
couraging. However, high quality evidence on the effi-
cacy of pIONM is missing. In order to close the gap, we
are conducting the first randomized multicenter trial
comparing urogenital and anorectal functional outcome




The primary objective of this trial is to assess urinary
functional outcome in rectal cancer patients undergoing
TME with pIONM, when compared to TME without
pIONM, in a 12 months follow-up period per patient.
The secondary objectives are to assess sexual and ano-
rectal functional outcome in rectal cancer patients
undergoing TME with pIONM, when compared to TME
without pIONM, in a 12 months follow-up period per
patient and to assess the safety, especially oncologic
safety and quality of TME.
Trial design
The NEUROS study is a prospective two-arm randomized
controlled multicenter clinical trial with a follow-up
period of 12 months per patient.
Centers currently participating:
Department of General Visceral and Transplant Surgery,
University Medicine of the Johannes Gutenberg-
University Mainz, Germany
Department of General and Visceral Surgery, University
Medical Center Göttingen, Germany
Department of General Surgery and Centre for Minimally
Invasive Surgery, Hannover Hospital (Siloah), Germany
Department of General Surgery, Schwarzwald-Baar-
Klinikum, Teaching Hospital of the University of Freiburg,
Villingen-Schwenningen, Germany
Department of General, Visceral, Transplantation, Vascular
and Thoracic Surgery, Ludwig Maximilians University
(LMU), Munich, Germany
Department of Surgery, University of Schleswig-Holstein
(UKSH), Campus Lübeck, Germany
Department of Visceral, Transplant, Thoracic and Vascular
Surgery, University Hospital of Leipzig, Germany
Study population
Patients undergoing TME for rectal cancer presenting at
one of the participating hospitals.
Inclusion criteria
 Histologically confirmed rectal cancer (≤ 16 cm
from anal verge)
 Suitable for radical surgery
 TME






 Partial mesorectal excision
 Transanal endoscopic microsurgery
 Ongoing infection or sepsis
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 Severe untreated physical or mental impairment
 Pregnancy or breastfeeding
 Women of childbearing potential who are not using
a highly effective birth control method
 Missing preoperative data on urogenital or anorectal
function
 Simultaneous participation in another clinical trial
 Previous participation in this clinical trial
 Lack of compliance with the trial procedure
Outcome measures
Assessment of urinary function is carried out on the
basis of the International Prostate Symptom Score (IPSS,
total score range from 0 to 35 points) and the Quality of
life index (Qol, Quality of life due to urinary symptoms,
total score range from 0 to 6 points) [10]. A higher score
indicates diminished urinary function and quality of life.
Previous studies reported that the IPSS also applies to
females and demonstrated that women have comparable
scores to those of age-matched men [11, 12].
Sexual function in females is evaluated with the Female
Sexual Function Index (FSFI) and in males with the Inter-
national Index of Erectile Function (IIEF). The FSFI has
been developed and validated as a brief, multidimensional
self-report instrument for assessing the key dimensions of
sexual function in women. It was designed and validated
for assessment of female sexual function and quality of life
in clinical trials and has demonstrated ability to discrimin-
ate between clinical and non-clinical populations [13]. The
FSFI is a 19-item questionnaire with a total score range
from 2 to 36 points. A lower score indicates diminished
sexual function. The IIEF has been developed and validated
as a brief and reliable self-administered scale for assessing
erectile function [14]. The IIEF is a 19-item questionnaire
with a total score range from 5 to 75 points. The brevity
and ease of comprehension of the measure provide prac-
tical advantages.
Anorectal function is determined by the Wexner-
Vaizey score (WVS) (minimum score = 0 = perfect con-
tinence; maximum score = 24 = totally incontinent) [15].
Sample size calculation
The rate of patients with an IPSS increased by at least 5
points 12 months after surgery compared to the pre-
operative IPSS is assumed to be 10 % in patients under-
going TME with pIONM. The corresponding rate for
patients undergoing TME without pIONM is expected
to be 30 %. A total number of 164 study patients is
needed to demonstrate a significant difference between
the study arms with a power of 90 % using Fisher’s exact
test (alpha = 0.05, two-sided). Dropout rates are expected
to be 2 % perioperatively and 10 % during the follow-up
period in both study arms resulting in an overall dropout
rate of 12 %. 188 patients have to be allocated to the
trial.
Withdrawal of study participants
Study participants can leave the study for the following
reasons:
 On the own request of the patient
 On the direction of the investigator, if a further
participation at the trial may be disadvantageous for
patient’s health
 If exclusion criteria become known
 Pregnancy
 Non-compliance
The investigator can decide to withdraw a participant
from the study for the above mentioned reasons. This
will be documented in the case report form (CRF) and
the physician is required to notify the Coordinating In-
vestigator. In all cases, the reason for withdrawal must
be recorded in the CRF and in the patient’s medical rec-
ord. All patients who discontinue because of adverse
events or clinical laboratory abnormalities should be
followed up until they recover or stabilize, and the sub-
sequent outcome should be recorded.
Replacement of study participants
Patients who underwent randomization and were with-
drawn will not be replaced.
Stopping rules for the whole trial
 New risks for subjects become known.
 Medical or ethical reasons affecting the continued
performance of the trial.
Endpoints
Primary endpoint
Primary endpoint is the increase of the IPSS by at least 5
points observed 12 months after surgery compared to
the preoperative IPSS per patient. In case of postopera-
tive urologic treatment for newly developed urinary dys-
function, primary endpoint is the increase of the IPSS by
at least 5 points observed before urologic treatment
compared to the preoperative IPSS. The primary end-
point is based on previous findings [16]. In a group of
61 patients undergoing mesorectal excision for rectal
cancer we observed long-term urinary deterioration in
13 patients determined by the IPSS. The median differ-
ence in the IPSS was 6 points (range: 1-25 points, inter-
quartile range: 4-8 points). Answers to additional
questions on the Qol ranged from 0 (delighted) to 6 (ter-
rible). We found that an increase of the IPSS by at least
5 points leads to a clear decrease in patients’ quality of
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life due to urinary symptoms (median difference in the
Qol score was 3 points (interquartile range: 2-4 points)).
Secondary endpoints
Secondary endpoint is the reduction of FSFI/IIEF by at
least 8/15 points 12 months after surgery compared to
the preoperative FSFI/IIEF per patient. The secondary
endpoint is analyzed separately for men and women. No
confirmatory analyses are planned for this endpoint. An-
other secondary endpoint is the change of the WVS ob-
served 12 months after surgery compared to the
preoperative score per patient. For assessment of safety,
especially oncologic safety adverse events, the rates of
pCRM-positive specimen (distance of tumor from cir-
cumferential resection margin ≤ 1 mm) and the quality
of TME will be documented. The quality of the mesorec-
tum is scored using the M.E.R.C.U.R.Y. grading (Grade I:
complete; Grade II: nearly complete; Grade III: incom-
plete) [17].
Randomization and blinding
All patients who meet the inclusion criteria will be random-
ized. Randomization ratio is 1:1 to TME with pIONM or
TME without pIONM (Fig. 1). Randomization is stratified
according to neoadjuvant therapy and gender using blocks
of variable length. Central randomization via FAX is
conducted in this study.
Prescreening / Screening and follow up
In patients undergoing neoadjuvant therapy a prescreen-
ing is scheduled 21 to 1 day before therapy begins. The
preoperative screening (baseline) is scheduled 14 to
1 day before TME. Study visits and follow up are sum-
marized in Fig. 2.
TME and pelvic intraoperative neuromonitoring
Total mesorectal excision
In surgical treatment of rectal cancer, adequate mesorec-
tal excision leads to an optimization of oncologic results.
For cancer in the middle and lower rectal third (≤12 cm
from the anal verge) a TME is recommended.
Neuromonitoring setup
Monitoring of the pelvic autonomic nerves is carried out
with a neuromonitoring system (504012 ISIS Touch and
accessories, CE 0297, inomed, Emmendingen, Germany),
which enables electric stimulation under simultaneous
observation of processed EMG signals of the IAS and
manometry of the urinary bladder. To observe IAS activ-
ity, bipolar needle electrodes (530228, CE 0297, inomed,
Emmendingen, Germany) are inserted transanally under
Fig. 1 Summary of study interventions/flow diagram. † In patients who did not undergo stoma closure, study visits are planed 6 and 12 months
after TME. Assessment of IIEF/FSFI and WVS will not be carried out. NT: Neoadjuvant therapy, TME: Total Mesorectal Excision, SC: Stoma closure,
IPSS: International Prostate Symptom Score, Qol: Quality of life due to urinary symptoms, IIEF: International Index of Erectile Function, FSFI: Female
Sexual Function Index, WVS: Wexner-Vaizey Score, pIONM: pelvic intraoperative neuromonitoring
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endosonographic guidance. The ground electrode
(530627, CE 0297, inomed, Emmendingen, Germany) is
placed on the left gluteal muscle and the electrodes are
connected to the neuromonitoring device. The imped-
ance is measured to ensure correct placement. Simultan-
eous observation of intravesical pressure is carried out
through the transurethral bladder catheter or if applic-
able suprapubic catheter. The catheter is connected to a
pressure transducer (520320, CE 0297, inomed,
Emmendingen, Germany), which is linked to the amp-
lifier of the neuromonitoring device. Thereby both
measurements could be continuously visualized as
neuromonitoring signals online on the screen of the
system. Before the onset of neurostimulation the bladder
is emptied and filled with 200 ml of Ringers’ solution.
Stimulation parameters are set to currents of 1-25 mA,
frequency of 30 Hz, and monophasic rectangular pulses
with pulse duration of 200 μs.
According to previous investigations a stimulation
dependent unilateral or bilateral consecutive increase in
intravesical pressure (cmH2O) or processed EMG ampli-
tude (V) of IAS will be rated as positive response verifying
functional integrity of urinary and anorectal innervation.
With regard to sexual function bilaterally observed posi-
tive results by manometry and IAS-EMG were valued as
preserved genital innervation [5, 6].
Pelvic intraoperative neuromonitoring (pIONM)
Stimulation of the pelvic autonomic nerve during mesor-
ectal dissection is performed by the surgeon with a
handheld bipolar microfork probe (EW0266 and 522027,
CE 0297, inomed, Emmendingen, Germany) and served
for identification and verification of functional nerve
integrity.
Initial neurostimulations are carried out bilaterally
after posterior/posterolateral mesorectal dissection in
Fig. 2 Frequency and scope of study visits
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order to detect the pelvic splanchnic nerves. Therefore,
bilateral repetitive stimulations along the pelvic sidewall
are carried out (stimulation period 3-10 seconds and
resting period in between the stimulations of 3-10
seconds) as a kind of neuromapping under continuous
observation of processed IAS-EMG. During ongoing lat-
eral mesorectal dissection neuromapping is performed
under simultaneous manometry of the urinary bladder
and IAS-EMG for identification of further potentially
surgical exposed nervous tissue (pelvic splanchnic nerves
S2-4, inferior hypogastric plexus).
Anterolateral mesorectal dissection is performed with
neuromapping under continuous processed IAS-EMG.
For quality assurance of the nerve-sparing technique
after TME (resection of specimen), the autonomic in-
nervation is finally verified by bilateral neuromapping
along the pelvic sidewall and just above the pelvic floor
under simultaneous manometry of the urinary bladder
and IAS-EMG. All observed neuromonitoring signals
are manually documented.
Statistical analysis
The primary analysis population for the efficacy parame-
ters is the intention-to-treat (ITT) population. The ITT
population includes all randomized patients for which a
preoperative and postoperative measurement of IPSS is
available. Patients will be analyzed in the treatment
group to which they were randomized. In addition, ana-
lyses for the Per-Protocol population will be performed.
Only patients with a minimum of compliance to the
study protocol will be included into the Per-Protocol
population. Relevant violations of the study protocol will
be defined in the statistical analysis plan, which is final-
ized before the database is closed and unblinded. Differ-
ences between rates of patients with an IPSS increased
by at least 5 points 12 months after surgery compared to
the preoperative IPSS will be evaluated using the
Wilcoxon signed rank test (two-sided, alpha = 0.05).
Patients for which no postoperative IPSS is available will
be excluded from the confirmatory analysis of the pri-
mary endpoint due to missing information about post-
operative urinary function. Missing IPSS scores
12 months after surgery will be imputed according to
the Last Observation Carried Forward (LOCF) method if
a postoperative IPSS is available. Postoperative IPSS
measured under the influence of additional therapies
against urinary dysfunction must not be used. Therefore,
the last observed IPSS before urologic treatment will be
analyzed. As dropout rates and imputed missing values
are expected to be equal in both study arms no selection
bias is expected by the application of these procedures.
The secondary outcome parameters will be analyzed
only descriptively. Preoperative IPSS, IPSS 12 months
after surgery and intra-individual changes of IPSS within
12 months after surgery will be analyzed by distribu-
tional parameters such as mean, median, range and
standard deviation separately for each study arm. An
analogous analysis will be performed for the IIEF in male
patients, the FSFI in female patients and the WVS. For
male patients the rates of patients with an IIEF reduced
by at least 15 points 12 months after surgery compared
to the preoperative IIEF score will be displayed separ-
ately for each study arm. For female patients these rates
will be calculated for the FSFI analogously. The thresh-
old for discretizing the change in FSFI within 12 months
after surgery is set to 8 points.
For the safety population summaries and listings of
safety data will be performed. Frequencies of subjects
experiencing at least one adverse event will be displayed
by body system and preferred term according to Med-
DRA terminology. Detailed information collected for
each adverse event will include: A description of the
event, duration, whether the adverse event was serious,
intensity, relationship to trial treatment, action taken
and clinical outcome. Summary tables will present the
number of subjects observed with adverse events and
corresponding percentages. Additional subcategories will
be based on event intensity and relationship to trial
treatment. A subject listing of all adverse events will be
prepared.
For the assessment of oncologic safety the rates of
pCRM-positive specimen and the quality of mesorectum
will be displayed by means of absolute and relative fre-
quencies separately for each study arm.
Ethical considerations
Assessment of risks and benefits
So far, there were no reports about differences in risk
potential for patients undergoing intraoperative electro-
physiological confirmation of pelvic autonomic nerves,
especially with regard to life threatening events. The in-
dividual participant will therefore not run any additional
risk during participation in this trial. The potential bene-
fit for the group of patients with additional pIONM is
the avoidance of pelvic autonomic nerve damage with
maintenance of quality of life, respectively. The intraop-
erative assessment of nerve-sparing and the predictabil-
ity of postoperative urogenital and anorectal functional
disturbances may offer secondary prevention with the
potential for an improved prognosis.
Care and protection of research participants
Nerve-sparing TME is a standard treatment for patients
with rectal cancer. There are no special adverse events
expected. Surrogate parameters of oncologic outcome
(rates of R1 and R2 resections, rates of pCRM-positive
specimen, and rates of incomplete mesorectal excision)
will be closely monitored by the Data Safety Monitoring
Kauff et al. BMC Cancer  (2016) 16:323 Page 6 of 9
Board (DMSB). All adverse events and serious adverse
events will be recorded. The serious adverse events will
be reported within 24 hours of the initial observation to
the Interdisciplinary Center for Clinical Trials (IZKS) at
the University Medicine of the Johannes Gutenberg-
University Mainz, Germany.
Availability of data and materials
The access to the confident patient information may be
granted only to the governmental bodies and authorized
representatives of the trial sponsor (clinical monitors).
Only patients who explicit consented to these provisions
will be enrolled in the clinical trial. The name of the
subjects and other confidential information are subject
to medical professional secrecy and the regulations of
the applicable local data protection regulations. During
the clinical trial, subjects will be identified by means of a
unique individual identification code (pseudonym). The
final trial report, public trial registers as well as scientific
publications will solely contain anonymized statistical
data.
Quality assurance / monitoring
The study will be continuously monitored by the clinical
research associates of the IZKS. Monitoring will be done
by personal visits, telephone and mail contacts by a clin-
ical monitor according to standard operating procedures.
All participating centers will be visited by the monitor to
ensure compliance with study protocol, good clinical
practice and legal aspects.
Safety
In this trial a DSMB will monitor and supervise the pro-
gress of the trial (including the safety data and the crit-
ical efficacy endpoints at intervals), review relevant
information from other sources, ensure adherence to
protocol, advise whether to continue, modify, or stop
this trial. Furthermore it will provide the funding
organization with information and advice. DSMB will
meet annually and on special request. The trial manage-
ment will organize these meetings and provide all neces-
sary information for the work of the data monitoring
board.
Trial status
The trial is ongoing and in the recruiting phase at the
time of manuscript.
Discussion
The TME within a modern multimodal treatment options
for rectal cancer resulted in a tremendous improvement
of oncologic outcome and cancer-specific survival while
dysfunction rates however remained still high. In conse-
quence maintaining quality of life receives particular
attention among colorectal surgeons aiming for best per-
formance of intraoperative nerve-sparing. This is rein-
forced by the fact that the incidence of colorectal cancer
diagnosed in young adults did significantly increase as
demonstrated by a recent retrospective cohort study in
393241 patients [18]. Based on current trends it was stated
that in 2030, the incidence rate for rectal cancer will in-
crease by 124.2 %, respectively, for patients 20 to 34 years
and by 46.0 %, respectively, for patients 35 to 49 years in
the United States.
The prerequisite for intraoperative pelvic autonomic
nerve preservation is the nerve identification. Only a few
authors reported their rather higher or lower nerve iden-
tification rates while many others do not specifically pro-
vide such information but state its difficulty [3, 19, 20].
In addition to knowledge about aggravating circum-
stances and confounding factors, the recognition of key
zones at risk of harm to the autonomic nerves is another
important step for improvement of the nerve-sparing
technique regardless of whether TME is performed min-
imally invasive or open via a transabdominal or transanal
approach [21, 22]. In order to master intraoperative
nerve-sparing the surgeon must rise to these challenges
and take the lead in shifting towards aiming for a more
sustainable quality of life.
The start however must be made in the informed con-
sent discussion. A recent survey of rectal cancer patients
undergoing surgery demonstrated that about 50 % of pa-
tients could not recall a preoperative discussion of risks
to urinary, sexual and bowel function. Interestingly, they
did desire more information regarding the occurrence of
these possible dysfunctions than information on cure
rate, need for second surgery, or the ability of surgery to
treat their symptoms [23].
The pIONM may offer improvement of intraoperative
nerve visualization and could be particularly beneficial
with regard to all the confounding factors. Nevertheless,
up to now there are no data from prospective random-
ized studies for comparing the functional outcome after
TME for rectal cancer with and without pIONM. The
aim of the present study is to evaluate whether pIONM
is a valuable method for maintaining patient’s urogenital
and anorectal function. This conducted prospective ran-
domized multicenter trial will thereby demonstrate the
efficacy, accuracy and safety of pIONM. Furthermore,
potential advantages or disadvantages of this method
can be analyzed. The study might also help to identify
patients who would particularly benefit from pIONM.
With a view to primary prevention, pIONM may repre-
sent a useful tool for improvement of the nerve-sparing
surgical technique in the minor pelvis. The additional qual-
ity assurance of pelvic autonomic nerve preservation after
TME with predictability of postoperative urogenital and
neurogenic ano(-neo)rectal dysfunctions could serve a
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secondary preventive function in enabling timely delivered
commencement of causal urological-/sexological and
proctological treatments with the potential for an improved
prognosis in those patients with functional disturbances.
This is the first randomized multicenter trial compar-
ing urogenital and anorectal functional outcome in rec-
tal cancer patients undergoing TME with and without
pIONM. If indeed found to be beneficial, pIONM will
offer maintenance of patients’ quality of life and possibly
decrease the amount of diagnostic and treatment costs
of postoperative functional disturbances.
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CRF: case report form; CRM: circumferential resection margin; DSMB: Data
Safety Monitoring Board; EMG: electromyography; FSFI: Female Sexual
Function Index; IAS: internal anal sphincter; IIEF: International Index of Erectile
Function; IPSS: International Prostate Symptom Score; ITT: intention-to-treat;
IZKS: Interdisciplinary Center for Clinical Trials; LOCF: last observation carried
forward; pIONM: pelvic intraoperative neuromonitoring; Qol: Quality of life
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Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
WK, KK and DW designed the study; DWK, WK, SG; KK and DW wrote the
protocol; DW conducted statistical trial planning; SG handled ethics and
regulatory affairs; KK and WK prepared the application for funding; DWK and
WK wrote the paper draft; SG, KK, DW and HL did the critical review; all
authors have approved the final version of the manuscript.
Acknowledgements
We would like to acknowledge A.-K. Kaiser for statistical support. Further we
would like to thank the following centers for their active commitment and
support:
Department of General and Visceral Surgery, University Medical Center
Göttingen, Germany (Prof. M. Ghadimi, MD); Department of General Surgery
and Centre for Minimally Invasive Surgery, Hannover Hospital (Siloah),
Germany (Prof. T. Moesta, MD); Department of General Surgery,
Schwarzwald-Baar-Klinikum, Teaching Hospital of the University of Freiburg,
Villingen-Schwenningen, Germany (Prof. N. Runkel, MD); Department of General,
Visceral, Transplantation, Vascular and Thoracic Surgery, Ludwig Maximilians
University (LMU), Munich, Germany (Prof. J. Werner, MD); Department of
Surgery, University of Schleswig-Holstein (UKSH), Campus Lübeck, Germany
(Prof. T. Keck, MD); Department of Visceral, Transplant, Thoracic and Vascular
Surgery, University Hospital of Leipzig, Germany (Prof. I. Gockel, MD).
Funding
The project is funded by grant from the German Research Foundation (DFG,
Grand number: KN 930/1-1).
Author details
1Department of General, Visceral and Transplant Surgery, University Medicine
of the Johannes Gutenberg-University, Mainz, Germany. 2Interdisciplinary
Center for Clinical Trials (IZKS), University Medicine of the Johannes
Gutenberg-University, Mainz, Germany. 3Boehringer Ingelheim Pharma GmbH
& Co. KG, Ingelheim, Germany.
Received: 15 September 2015 Accepted: 11 May 2016
References
1. Haim N, Wexner SD. Rectal Cancer-Associated Urinary Dysfunction: a
Review. Curr Bladder Dysfunct Rep. 2015;10:118–24.
2. Kneist W. Erhaltung der autonomen Nerven bei TME; in Korenkov M,
Germer CT, Lang H (eds): Gastrointestinale Operationen und technische
Varianten, Springer-Verlag Berlin Heidelberg, ISBN-13 978-3-642-32258-7,
2013:367-381.
3. Lange MM, Martz JE, Ramdeen B, Brooks V, Boachie-Adjei K, van de Velde CJ,
Enker WE. Long-term results of rectal cancer surgery with a systematical
operative approach. Ann Surg Oncol. 2013;20:1806–15.
4. Costanzi A, Rigamonti L, Mari GM, Miranda A, Crippa J, Berardi V, Maggioni D.
A prospective video-controlled study of genito-urinary disorders in 35
consecutive laparoscopic TMEs for rectal cancer. Surg Endosc. 2015;29:1721–8.
5. Kneist W, Junginger T. Intraoperative electrostimulation objectifies the
assessment of functional nerve preservation after mesorectal excision. Int J
Colorectal Dis. 2007;22:675–82.
6. Kauff DW, Koch KP, Somerlik KH, Hoffmann KP, Lang H, Kneist W. Evaluation
of two-dimensional intraoperative neuromonitoring for predicting urinary
and anorectal function after rectal cancer surgery. Int J Colorectal Dis.
2013;28:659–64.
7. Kneist W, Kauff DW, Rubenwolf P, Thomas C, Hampel C, Lang H. Intraoperative
monitoring of bladder and internal anal sphincter innervation: a predictor of
erectile function following low anterior rectal resection for rectal cancer?
Results of a prospective clinical study. Dig Surg. 2013;30:459–65.
8. Kneist W, Kauff DW, Juhre V, Hoffmann KP, Lang H. Is intraoperative
neuromonitoring associated with better functional outcome in patients
undergoing open TME? Results of a case-control study. Eur J Surg Oncol.
2013;39:994–9.
9. Fang JF, Wei B, Zheng ZH, Chen TF, Huang Y, Huang JL, Lei PR, Wei HB.
Effect of intraoperative autonomic nerve stimulation on pelvic nerve
preservation during radical laparoscopic proctectomy. Colorectal Dis. 2015
Sep 12. doi: 10.1111/codi.13115. [Epub ahead of print]
10. Denis L, Griffiths K, Khoury S. Measuring the symptom and health impact of
benign prostatic hyperplasia and its treatment. In: Denis L, Griffiths K,
Khoury S, et al., editors. 4th international consultation on benign prostatic
hyperplasia. 4th ed. Paris: World Health Organization, Health Publication Ltd;
1998. p. 265–80.
11. Lepor H, Machi G. Comparison of AUA symptom index in unselected males
and females between fifty-five and seventy-nine years of age. Urology.
1993;42:36–41.
12. Madersbacher S, Pycha A, Klingler CH, Schatzl G, Marberger M. The
international prostate symptom score in both sexes: a urodynamics-based
comparision. Neurourol Urodynam. 1999;18:173–82.
13. Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, Ferguson D,
D'Agostino R Jr.. The Female Sexual Function Index (FSFI): a
multidimensional self-report instrument for assessement of female sexual
function. J Sex Marital Ther. 2000;26:191–208.
Kauff et al. BMC Cancer  (2016) 16:323 Page 8 of 9
14. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The
International Index of Erectile Function (IIEF): a multidimensional scale for
assessment of erectile dysfunction. Urology. 1997;49:822–30.
15. Vaizey CJ, Carapeti E, Cahill JA, Kamm MA. Prospective comparison of faecal
incontinence grading systems. Gut. 1999;44:77–80.
16. Kneist W, Junginger T. Long-term urinary dysfunction after mesorectal
excision: a prospective study with intraoperative electrophysiological
confirmation of nerve preservation. Eur J Surg Oncol. 2007;33:1068–74.
17. Nagtegaal ID, van de Velde CJ, van der Worp E, Kapiteijn E. Quirke P,
van Krieken JH; Cooperative Clinical Investigators of the Dutch
Colorectal Cancer Group: Macroscopic evaluation of rectal cancer
resection specimen: clinical significance of the pathologist in quality
control. J Clin Oncol. 2002;20:1729–34.
18. Bailey CE, Hu CY, You YN, Bednarski BK, Rodriguez-Bigas MA, Skibber JM,
Cantor SB, Chang GJ. Increasing disparities in the age-related incidences of
colon and rectal cancers in the United States, 1975-2010. JAMA Surg.
2015;150:17–22.
19. Grama F, Aslan D, Burcos T, Richiteanu G, Cristian D. Evaluation of the
male sexual and urinary functions after open rectal cancer surgery – A
questionnaires based study. Archives of the Balkan Medical Union.
2015;50:9–17.
20. Andersson J, Abis G, Gellerstedt M, Angenete E, Angerås U, Cuesta MA, Jess P,
Rosenberg J, Bonjer HJ, Haglind E.. Patient-reported genitourinary dysfunction
after laparoscopic and open rectal cancer surgery in a randomized trial
(COLOR II). Br J Surg. 2014;101:1272–9.
21. Moszkowicz D, Alsaid B, Bessede T, Penna C, Nordlinger B, Benoît G,
Peschaud F. Where does pelvic nerve injury occur during rectal surgery for
cancer? Colorectal Dis. 2011;13:1326–34.
22. Kneist W, Rink AD, Kauff DW, Konerding MA, Lang H. Topography of the
extrinsic internal anal sphincter nerve supply during laparoscopic-assisted
TAMIS TME: five key zones of risk from the surgeons’ view. Int J Colorectal
Dis. 2015;30:71–8.
23. Scheer AS, O'Connor AM, Chan BP, Moloo H, Poulin EC, Mamazza J, Auer RC,
Boushey RP. The myth of informed consent in rectal cancer surgery: what do
patients retain? Dis Colon Rectum. 2012;55:970–5.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Kauff et al. BMC Cancer  (2016) 16:323 Page 9 of 9
